ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 90 Publications

16 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • 3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
Bfl-1 [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50) >10 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoT6NlUxKG6PwrC= MV[3NkBp Mli2SG1UVw>? NX;5W2lR[2G3c3XkJFk4LSCub4PzJI9nKH[rYXLpcIl1gSCrbjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEKFTE[gd4lTVkF? M4n0dFI3PjV5Mki4
KG1a M2LhZ2NmdGxiVnnhZoltcXS7IFHzd4F6 Mo\2NE0yOCEQvF2= NUjHc2RrOjRiaB?= NXO4cY1KTE2VTx?= MlLlTWM2OD15Lk[4JO69VSxiZHXjdoVie2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYiyOlU2OjdzMh?=
Kasumi-1 MmPHR4VtdCCYaXHibYxqfHliQYPzZZk> NH:1U5YxNTFyIN88US=> MXuyOEBp NH\IcGhFVVOR M3fmSmlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYeyOlU2OjdzMh?=
KG1a Mnj2RZBweHSxc3nzJGF{e2G7 NUDre2R5OC1zMDFOwG0> MlfuNlQhcA>? NHfTSnBFVVOR M2nSTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVHsTFRrOjZ3NUK3NVI>
Kasumi-1 NYTZWJltSXCxcITvd4l{KEG|c3H5 NYewfGVVOC1zMDFOwG0> MmHjNlQhcA>? NFH0[nBFVVOR NXTIfo93cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVPZcJZqOjZ3NUK3NVI>
MC-3  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\KeotkPS9zMD:yNEDPxE1? NF;Y[YQzPCCq NYrTeFdyTE2VTx?= MnnWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4P1TVI3PDR5NkG1
HN22  NIG5cWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSyMlUwPy53L{KyMlUh|ryP Mm\jNlQhcA>? NV:0OnYyTE2VTx?= NWTMeY8{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4rCOVI3PDR5NkG1
MC-3  M1PjW2Fxd3C2b4Ppd{BCe3OjeR?= NFXLZmE2NzFyL{KwJO69VQ>? NGr5TmwzPCCq NGHiUHhFVVOR NWXJRYlNcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NXi5To1WOjZ2NEe2NVU>
HN22  MnXQRZBweHSxc3nzJGF{e2G7 MVGyMlUwPy53L{KyMlUh|ryP NWW0cY1TOjRiaB?= NGjDOmhFVVOR MYTpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| MmLtNlY1PDd4MUW=
MOLT-4 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DleVExNTVyMECgcm0> MoPSO|IhcA>? NYXPVY04TE2VTx?= M{T6NWlEPTB;MD6xPVgh|ryP MkTXNlY{QTJ|M{K=
RS4;11 NWLaW|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrMVYIyOC13MECwJI5O M2OzcFczKGh? MlrQSG1UVw>? M33aS2lEPTB;MD6wNFIh|ryP M{P5NFI3Ozl{M{Oy
JURKAT M3;YS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnufVFGOTBvNUCwNEBvVQ>? Ml3RO|IhcA>? MWrEUXNQ MmnMTWM2OD14NjFOwG0> M4rQfVI3Ozl{M{Oy
CEM R NFHMUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHyNVAuPTByMDDuUS=> NXnLWI1rPzJiaB?= M{jKSmROW09? MYLJR|UxRTVwNDFOwG0> NFSyXGkzPjN7MkOzNi=>
CEM S MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vXW|ExNTVyMECgcm0> NWTsSmJ7PzJiaB?= NHO0fHhFVVOR MUXJR|UxRTF{LkGg{txO MVOyOlM6OjN|Mh?=
MOLT-4 MXrBdI9xfG:|aYOgRZN{[Xl? MXWxNE0yODByIH7N MkXNNlQhcA>? NIXofoZFVVOR M{nDPYNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x Mn7INlY{QTJ|M{K=
CEM S MV3BdI9xfG:|aYOgRZN{[Xl? NGPvU4QyOC1zMECwJI5O NVr3b|cyOjRiaB?= NXvyWJZ2TE2VTx?= NX7rVW5p[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> NITYeIUzPjN7MkOzNi=>
JURKAT Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLQNVAxNTFyMECgcm0> NX7ybFVNPDhiaB?= MnjQSG1UVw>? NUfEUXdFUUN3ME25OVXDuTlwMzDuUS=> M2n4[FI3OTd{Mk[5
LOUCY M33jfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNFAuOTByMDDuUS=> NWrIVJpOPDhiaB?= MXLEUXNQ MUTJR|UxRTN{LklCtVExNjlibl2= MkW0NlYyPzJ{Nkm=
WM-115 NF\yNmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoLSNVAxyqCwTR?= NXXRN5JOPzJiaB?= M4HndoVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi MkXaNlYyOTZ5N{[=
B16 NGmyRYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlTwNVAxyqCwTR?= NXLs[YEzPzJiaB?= M4DTPYVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi NEnN[mYzPjFzNke3Oi=>
HL-60  M1v5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu3NkBp M2HmWWlEPTEEoE2gNVAvPyCwTR?= NYD3SVRwOjZyNEW2NFk>
MOLM-13  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL0O|IhcA>? M2HONmlEPTEEoE2gNlcvQSCwTR?= MlfxNlYxPDV4MEm=
OCI-AML3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp MmHFTWM2OMLiPTCxPVUxKG6P NEXFZlMzPjB2NU[wPS=>
BCWM.1 NXjMVlNpSXCxcITvd4l{KEG|c3H5 MlzmNE0yNjZizszN NUTCSG5FOjRiaB?= M2LTUolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1P2ZVI2QDl|Mkmw
MWCL-1 MVrBdI9xfG:|aYOgRZN{[Xl? M3ewWFAuOS54IN88US=> NXn0e2sxOjRiaB?= M{XkT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mk\3NlU5QTN{OUC=
MM.1s NVX0b5NmSXCxcITvd4l{KEG|c3H5 NEL5WoIxNTFwNjFOwG0> MlPUNlQhcA>? NGCyUWRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MVWyOVg6OzJ7MB?=
HCT116 MmK1SpVv[3Srb36gRZN{[Xl? M4riNlMwOTBizszN MXyxNuKhcMLi NH\UU|NFVVOR MmK1bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NFWxdXIzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO NVi3WVN6TnWwY4Tpc44hSXO|YYm= MUOzM|ExKM7:TR?= NE[wfnIyOsLiaNMg MofDSG1UVw>? NEH6bXZqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36= NX7rV5c{OjV5MUWwNlg>
HCT116 M1\6NWZ2dmO2aX;uJGF{e2G7 NG[wV3UyOCEQvF2= NGH5VosyOsLiaNMg NFjOVHNFVVOR MYfpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj M3fVN|I2PzF3MEK4
HCT116 BAX BAK1 DKO MXnGeY5kfGmxbjDBd5NigQ>? M4e5ZlExKM7:TR?= NXHEb4REOTMEoHlCpC=> M{LxXWROW09? NUHTdVJbcW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> NVfBSY0yOjV5MUWwNlg>
HCT116 MlHvRZV1d3CqYXf5JGF{e2G7 MUixNEDPxE1? NF2wem0yOsLiaNMg M2jJU2ROW09? M2XtN4lv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm NH7JNVgzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO M4LKOWF2fG:yaHHnfUBCe3OjeR?= MoLlNVAh|ryP MkHlNVLDqGkEoB?= NFzFXmhFVVOR MWfpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NITjUG4zPTdzNUCyPC=>
U937 NGj1ZZZCeG:ydH;zbZMhSXO|YYm= NX;sR2JlOC5zMkWtNkDPxE1? MY[yOEBp Mof5[Y5p[W6lZYOgSGhCN1hvMUGtbY5lfWOnZDDhdI9xfG:|aYO= M4qxZlI2PzF2MEK0
U937  NVfUSVZTSXCxcITvd4l{KEG|c3H5 M1T3UlAvPSEQvF2= NWLDNVUzOjRiaB?= MljB[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{KGG|IIflcIwh[XNiTn;4ZUBt\X[nbB?= NIHsfVQzPTdzNECyOC=>
HL-60 AAA-Bcl-2 NH;qd3lCeG:ydH;zbZMhSXO|YYm= NWjrO3R6OC13IN88US=> MmjhOFghcA>? MnzQTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmLJNlU4OTF2NkC=
HL-60 EEE-Bcl-2 M4LoU2Fxd3C2b4Ppd{BCe3OjeR?= MoT1NE02KM7:TR?= MYO0PEBp M3vZemlEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlnHNlU4OTF2NkC=
U87 M1eycWZ2dmO2aX;uJGF{e2G7 NFi3SVA2OCEQvF2= NFH6d2EzPCCq MnXBdoVlfWOnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBOVVBvMjygUW1RNTF2IHHu[EBD[2xvMh?= NXr1bXpvOjV4Nke2OlM>
K562 NUG4NFU1S2WubDDWbYFjcWyrdImgRZN{[Xl? NFjkOGQyNTFyIN88US=> NYT5c4JoPDhiaB?= Moi5SG1UVw>? M4r6TGlEPTB;Mk[uO{DPxE1? MVmyOVU6PjV4MR?=
K562/Mcl -1-IRESBim MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7yTWM2OD17LkOg{txO M3HKVlI2PTN3OUCw
K562/Bcl- 2-IRESBim MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn4WZU{UUN3ME2wMlM2KM7:TR?= NWLQ[|hOOjV3M{W5NFA>
Jurkat NUDC[2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK5TWM2OD1yLk[2JO69VQ>? MUCyOVU{PTlyMB?=
JurkatΔBak M4jHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTu[VhKSzVyPkWwJO69VQ>? MnTCNlU2OzV7MEC=
HL60/VCR NXLYXJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRjFyMDFOwG0> NWHNRoxpOjV3M{W5NFA>
Kasumi-1 M3e5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIOWlEPTB;MD6wNUDPxE1? MlPUNlU2OzV7MEC=
Kasumi-1/ABT MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzSb3NKSzVyPUCuOVEh|ryP M1ThblI2PTN3OUCw
THP-1 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz1W49KSzVyPUGuNlch|ryP MknaNlU2OzV7MEC=
U937 NEnOXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[wTWM2OD13LkK5JO69VQ>? NIPRcIUzPTV|NUmwNC=>
C1498 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjt[oFKSzVyPU[uNVMh|ryP NWDxdXhxOjV3M{W5NFA>
RPMI 8226 NVrsOHdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD3TWM2OD1yLkK1JO69VQ>? MVyyOVU{PTlyMB?=
MM.1S MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVOWlEPTB;MD60NEDPxE1? MWWyOVU{PTlyMB?=
NCI-H929 NXj6TW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXtTWM2OD1zNT6yNUDPxE1? NILjV4czPTV|NUmwNC=>
U266 NV7xSYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PpcGlEPTB;MD62PEDPxE1? MoLDNlU2OzV7MEC=
MCF-7 M2HzeWNmdGxiVnnhZoltcXS7IFHzd4F6 NHvJOXM2KM7:TR?= NEPlNYo1QCCq M4[zeWROW09? M4f6ZoVvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? NGO2S5QzPTRyOUGyOC=>
MCF-7 NHfhS5hCeG:ydH;zbZMhSXO|YYm= NGnEc4Q2KM7:TR?= NV;senlNPC9{ND:0PEBp M3;xbmROW09? M3fiVIlv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ Mn3PNlU1ODlzMkS=
MCF-7 MnHJSpVv[3Srb36gRZN{[Xl? M3vnOlUh|ryP MnSyNlQhcA>? NUnVPIpwTE2VTx?= MkXo[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NIG5e|kzPTRyOUGyOC=>
MDA-MB 231  MV;GeY5kfGmxbjDBd5NigQ>? NH7sSHE2KM7:TR?= M4Prd|I1KGh? NWXYcGlNTE2VTx?= NVPFV4tE\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi NWfRfmx6OjV2MEmxNlQ>
ZR-75-1  M3TSO2Z2dmO2aX;uJGF{e2G7 MX61JO69VQ>? M3\Ge|I1KGh? NGTKTHlFVVOR NYPMelBI\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi M3XWSVI2PDB7MUK0
A549 NH7KWGhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NULhRoduOC1{MDFOwG0> MnPxO|IhcA>? NHLLZldFVVOR M3qxVoRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NYnNOm9POjV|OEi3OlI>
H1299 MmT5R4VtdCCYaXHibYxqfHliQYPzZZk> MXewMVIxKM7:TR?= M1j5eFczKGh? Mn7ZSG1UVw>? MWPk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv M13xUVI2Ozh6N{[y
HO-8910 M{fC[GNmdGxiVnnhZoltcXS7IFHzd4F6 M3\tNVAuOjBizszN NWnyb2E5PzJiaB?= MojmSG1UVw>? MVXk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MlzsNlU{QDh5NkK=
HT-29 Mn;wR4VtdCCYaXHibYxqfHliQYPzZZk> M17LXFAuOjBizszN NUXNZW1SPzJiaB?= M4KzVGROW09? MnLZ[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NV24boJ6OjV|OEi3OlI>
HCT-116 NVzNWFJtS2WubDDWbYFjcWyrdImgRZN{[Xl? MXuwMVIxKM7:TR?= NHO4T204OiCq M2juWmROW09? MoTN[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M1T4SFI2Ozh6N{[y
A549 MmGzRZBweHSxc3nzJGF{e2G7 NVj5cpJvOjBizszN MVm0PEBp MnHqSG1UVw>? Mo\PbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= NXjhTJRsOjV|OEi3OlI>
H1299 NIL3RlVCeG:ydH;zbZMhSXO|YYm= M3LRflIxKM7:TR?= MV60PEBp NHrkfXRFVVOR M173T4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu NInIdHozPTN6OEe2Ni=>
Sc-1 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF3wSJMxNjByMEGtNUDPxE1? NH6yPVA6PiCq Mo\6[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3LMUFI2Ozd|NUC4
OcI-LY18 NFH6Z2VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYiwMlAxODFvMTFOwG0> MYC5OkBp NH7uS3Nl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1LC[|I2Ozd|NUC4
RL  M{LCTmNmdGxiVnnhZoltcXS7IFHzd4F6 MmPGNE4xODBzLUGg{txO NVrzPW11QTZiaB?= MUfk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVyyOVM4OzVyOB?=
RKO NVrNdlVjS2WubDDWbYFjcWyrdImgRZN{[Xl? MVKwMVExKM7:TR?= M2LIOlI16oDLaNMg MnfGSG1UVw>? MlPpTWM2OD8kgJmyOgKBkcL3TR?= Mo\wNlU{ODR|OEO=
Caco-2 MlXNR4VtdCCYaXHibYxqfHliQYPzZZk> MWGwMVExKM7:TR?= M{fw[FI16oDLaNMg M2TKUWROW09? NXHEZpFEUUN3ME2xPU446oDLwsXN NFfRV3MzPTNyNEO4Ny=>
DLD1 M13idGNmdGxiVnnhZoltcXS7IFHzd4F6 NGjZV4ExNTFyIN88US=> NIn6XVMzPOLCiXlCpC=> NGToVmZFVVOR NUn0WFJtUUN3ME2xPE44QOLCidM1US=> MUOyOVMxPDN6Mx?=
LS411N M3fnfmNmdGxiVnnhZoltcXS7IFHzd4F6 NITwZYsxNTFyIN88US=> M3;INlI16oDLaNMg Mor0SG1UVw>? M4TPOGlEPTB;MUGuOFfjiIoEtV2= M3q4O|I2OzB2M{iz
SW620 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\1ZVAuOTBizszN M2XRZ|I16oDLaNMg M1\1R2ROW09? NEnnWHJKSzVyPUGyMlI16oDLwsXN NEXUSWQzPTNyNEO4Ny=>
HCT116 NXm4RYs2S2WubDDWbYFjcWyrdImgRZN{[Xl? MXiwMVExKM7:TR?= MnLvNlTjiImqwrC= Mo\CSG1UVw>? M2DsZmlEPTB;MkCuOFnjiIoEtV2= MYmyOVMxPDN6Mx?=
HaCaT MlL6R4VtdCCYaXHibYxqfHliQYPzZZk> MoTsNE4yNzFxMUCg{txO NHqyZXUzPCCq MV;EUXNQ M2nnO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlXjNlUzOTB5OUW=
A5-RT3 MofsR4VtdCCYaXHibYxqfHliQYPzZZk> MX:wMlEwOS9zMDFOwG0> NYjPUIFrOjRiaB?= NV3UcnlFTE2VTx?= MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo[3NlUzOTB5OUW=
HaCaT M16zR2Z2dmO2aX;uJGF{e2G7 M1TnVFEx6oDLzszN NG\OTGszPC92ODDo M1\VR2ROW09? M{PxR4lv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= MViyOVIyODd7NR?=
A5-RT3 NYX6dlRNTnWwY4Tpc44hSXO|YYm= Ml;rNVDjiIoQvF2= NVHER2c6OjRxNEigbC=> M{\MfGROW09? MUjpcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? MW[yOVIyODd7NR?=
A5-RT3 Mm\ESpVv[3Srb36gRZN{[Xl? NVXNT|lJPSEQvF2= MWG2JIg> NH;iWHFFVVOR NEPYPXZqdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz MoOwNlUzOTB5OUW=
U266 M4jLXWZ2dmO2aX;uJGF{e2G7 M4q0NFUxOC95NUCgcm0> Mn3uNlQwPDhiaB?= MoD5SG1UVw>? M2G3dIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> Mn7GNlUzODh6OEi=
RPMI8226 MlKzSpVv[3Srb36gRZN{[Xl? NVHHfIhYPTByL{e1NEBvVQ>? MXyyOE81QCCq MnftSG1UVw>? MYfkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= NUnmcFB5OjV{MEi4PFg>
MM.1S MorKSpVv[3Srb36gRZN{[Xl? NXTpOWlWPTByL{e1NEBvVQ>? NInpdo0zPC92ODDo M{HMUmROW09? MVLkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M3XKVVI2OjB6OEi4
Clone A NW[zWXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvad4NHOC5{4pETOlAh|ryP NHGxZng4OiCq M4j3eWROW09? Mnm1TWM2OD15LkWg{txO NEPvV2QzPTJyOEi4Ni=>
CX-1 NH7mbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7MNE4z6oDVNkCg{txO MnOwO|IhcA>? NFX4THNFVVOR MVTJR|UxRTFwODFOwG0> NGL3ZZozPTJyOEi4Ni=>
LS174T MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlruNE4z6oDVNkCg{txO NV;6cFM4PzJiaB?= M4\PS2ROW09? NEfkOWVKSzVyPUG4MlMh|ryP M4fCXFI2OjB6OEiy
HT29 MmjaRZBweHSxc3nzJGF{e2G7 MU[xM|UwOTBizszN Ml\pOFghcA>? M{X6XoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmKwNlUyQTJzOEi=
SW480 MnTJRZBweHSxc3nzJGF{e2G7 NWPBUlA3OS93L{GwJO69VQ>? NEf6e|k1QCCq M4HpbYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkTFNlUyQTJzOEi=
Colo205 M1jkZmFxd3C2b4Ppd{BCe3OjeR?= M{TET|EwPS9zMDFOwG0> MYS0PEBp M3TJXINifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4XRe|I2OTl{MUi4
Caco2 M2ruXWFxd3C2b4Ppd{BCe3OjeR?= MkHUNU82NzFyIN88US=> MoDiOFghcA>? M{jZdYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MojkNlUyQTJzOEi=
PCI-13 NVrZNG1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj0NWhTPzJiaB?= M3vDeGROW09? MljQS2k2OD1zNTFCtUAyNjhizszN MlXsNlUyOzl|OEe=
PCI-15B NX76WYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G4cFczKGh? M1;yWmROW09? NEXhbmxIUTVyPUGxJOKyKDRwNTFOwG0> NXXyb4tNOjVzM{mzPFc>
UM-SCC22B NGXBcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO3O|IhcA>? NHuyUnVFVVOR MVPHTVUxRTF7INMxJFIvQSEQvF2= MWOyOVE{QTN6Nx?=
UM-SCC47 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm3NkBp NITKWoRFVVOR NULZ[mxmT0l3ME2xPUDDuSBzMj6zJO69VQ>? NYjx[2dQOjVzM{mzPFc>
93-VU-147T M2jheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3xVFA4OiCq MUTEUXNQ M3O2TmdKPTB;ND6zJOKyKDNwNTFOwG0> MXOyOVE{QTN6Nx?=
UD-SCC2 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKyO|IhcA>? MmPSSG1UVw>? NGO0VYlIUTVyPUK4JOKyKDJwOTFOwG0> Mn7LNlUyOzl|OEe=
UPCI:SCC90 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\1O|IhcA>? M2nKT2ROW09? NGnOTnJIUTVyPU[uOkDDuSBzLkWg{txO M2i3UFI2OTN7M{i3
RPMI-8226  NV;USXRGS2WubDDWbYFjcWyrdImgRZN{[Xl? MkX3NVI2NzJ3MD:1NFAhdk1? MV:0PIjDqA>? Mnz5SG1UVw>? MkHs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnzkNlUxODh{MEK=
OPM-2  M{jrSmNmdGxiVnnhZoltcXS7IFHzd4F6 MXqxNlUwOjVyL{WwNEBvVQ>? NE\FdY81QGkEoB?= MmTUSG1UVw>? NXvJSWdv\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWiyOVAxQDJyMh?=
RPMI-8226  M2\MUmFxd3C2b4Ppd{BCe3OjeR?= NIfueosyOjVxMkWwM|UxOCCwTR?= MoDzOFhpyqB? MYHEUXNQ MmrubY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1X2fVI2ODB6MkCy
OPM-2  NUGxR3VSSXCxcITvd4l{KEG|c3H5 MmDHNVI2NzJ3MD:1NFAhdk1? NGPvV4Q1QGkEoB?= Mn;xSG1UVw>? M4freolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2HDPVI2ODB6MkCy
COG-LL-319 MWLGeY5kfGmxbjDBd5NigQ>? NIPZSGwyODBibl2= MYCxM|MwPiCq NVPrO|I{TE2VTx?= MXLpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm NWX3UZJNOjR7NUG0O|I>
RS4;11 MXnGeY5kfGmxbjDBd5NigQ>? NG[2eYcyODBibl2= NYXDcVF3OS9|L{[gbC=> MXrEUXNQ NVntZYFYcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= MkXWNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID